Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

Safety and Outcomes of CD19 CAR-T Cell Therapy in Splenectomized Patients With B-Cell Lymphomas.

Transplantation and cellular therapy·2026
Same author

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study.

Hematological oncology·2026
Same author

Favorable safety and efficacy profiles of α-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-<i>versus</i>-host disease of the gastrointestinal tract: a retrospective, single center study.

Haematologica·2026
Same author

Local cytokine release syndrome with cervical angioedema following CAR-T cell therapy.

Haematologica·2026
Same author

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.

Annals of hematology·2026

Related Experiment Video

Updated: Feb 24, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.9K

Allogeneic stem-cell transplantation for myelofibrosis.

Noa Lavi1, Jacob M Rowe, Tsila Zuckerman

  • 1aDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa bDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem cRuth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Current Opinion in Hematology
|August 24, 2017
PubMed
Summary

Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative option for myelofibrosis. Advances in patient selection, donor matching, and supportive care are improving outcomes, even with JAK inhibitor use.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Related Experiment Videos

Last Updated: Feb 24, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.9K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only curative treatment for myelofibrosis.
  • HSCT use has increased despite the advent of Janus kinase (JAK) inhibitors like ruxolitinib.
  • Improved patient selection and supportive care contribute to better HSCT outcomes.

Purpose of the Study:

  • To review recent advancements in HSCT for myelofibrosis.
  • To discuss patient selection, including molecular risk stratification.
  • To examine the role of JAK inhibitors in the peritransplant period.

Main Methods:

  • Literature review of recent updates on HSCT in myelofibrosis.
  • Analysis of predictors for transplant outcomes.
  • Consideration of peritransplant management strategies.

Main Results:

  • Recent advances refine HSCT eligibility and timing.
  • Molecular risk stratification aids patient selection.
  • Management strategies for the peritransplant period are evolving.

Conclusions:

  • HSCT remains a vital curative therapy for myelofibrosis.
  • Advances enhance HSCT eligibility, timing, and post-transplant care.
  • The integration of JAK inhibitors requires careful consideration in HSCT protocols.